It’s been a heck of a week (and it’s only Tuesday).
Today on Post-Hoc Live, I chatted with my colleague at the Financial Times, Global Pharmaceutical Editor Hannah Kuchler. Next week, we’ll both be in London for the FT and Endpoints News Global Pharma and Biotech Summit, and we wanted to give you a preview of what we’ll be talking about, and also how we’re thinking about some of the very busy, very chaotic stories we’re both covering right now.
You can watch on YouTube.
Hannah and I talked about the latest M&A drama between Pfizer, Metsera and Novo Nordisk just as Pfizer’s earnings call is wrapping up. We’ll chatted about the new Novo and its aggressive CEO. We’ll got into all things Washington, D.C., from the turmoil at the FDA to how we think the next round of MFN announcements will go. And Hannah shared her view from the UK on how our friends in Europe look at what’s happening here in the US.
If you’re in London, or you’d like to join us virtually next week, you can check out the agenda for the Global Pharma and Biotech Summit that starts Nov. 11. (You can use the code POSTHOC20 to save on your virtual registration.)
Hope to see you there!
— Drew
↧